76results about "Libraries" patented technology

Compositions, methods and systems for targeted delivery using one or more shuttles operably linked to one or more cargos (e.g., cargo polypeptides, e.g., cargo oligonucleotides) and subsequent quantification of an abundance of one or more cargos (e.g, proteins) in a mixture (e.g., a complex mixture (e.g., in vivo)) or in a specific cell, tissue, or organ of interest (e.g., in vivo) using barcodes (e.g., peptide barcodes), binders (e.g., polypeptide binders), and binding agents (e.g., phage) are provided herein.

Anti-GCC single domain antibodies (e.g., VHH domain antibodies) and chimeric antigen receptors (CARs) that bind to GCC are provided, wherein the chimeric antigen receptors (CARs) comprise the anti-GCC single domain antibody in an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signaling domain. Immune cells transduced with the disclosed CAR constructs and / or chimeric receptors can be used in cancer immunotherapy.

To provide improved therapeutic approaches for treating small cell lung cancer (SCLC) and other DLL3 (delta-like ligand 3)-expressing cancers.SOLUTION: Provided is a chimeric antigen receptor (CAR) comprising a DLL3-binding domain, the DLL3-binding domain comprising or being derived from a single domain antibody (sdAb) or a single chain variable fragment (scFv).SELECTED DRAWING: None

Compositions and methods are provided that include binding partners that specifically bind to peptide conjugate / MHC complexes, including peptide conjugates formed by covalent reaction of a targeted covalent inhibitor with a peptide. The binding partners are provided as antibodies and antibody derivatives that specifically bind to the peptide conjugate / MHC complex.

In this specification, in an aspect, compositions, methods, kits and systems are disclosed relating to the efficient delivery of a freight (e.g., a therapeutic freight) to cells, for example, for in vivo delivery. More specifically, the delivery vehicle is a lipid-containing particle comprising (a) a human endogenous retrovirus (HERV) envelope protein, a humanized envelope protein, or a non-immunogenic membrane fusion molecule, (b) a combinatorial protein comprising a plasma membrane-localized protein, and (c) a freight.

The present invention provides a method for constructing and applying multivalent protein drugs and vaccines via nucleic acid multimerization. Specifically, the present invention provides a multimeric complex based on a complementary nucleic acid backbone, which is a multimer formed by complexing three to six monomers having a complementary nucleic acid backbone, where each monomer is a polypeptide having a single nucleic acid strand. In the multimer, the single nucleic acid strand of each monomer and the single nucleic acid strands of the other two monomers form a double strand through base complementarity, thereby forming a complementary nucleic acid backbone structure. The present invention also provides a pharmaceutical composition containing the multimeric complex, a nucleic acid sequence library for constructing the multimeric complex, and a method for optimizing the complementary nucleic acid backbone. The present invention also provides a method for completing the multivalency of off-the-shelf short-acting protein drugs or antigens, improving their half-life, activity, and / or immunogenicity, without the need for fusion protein reconstruction or chemical modification and crosslinking.

To provide a novel approach for the treatment of lung cancer.SOLUTION: T cells, particularly CD8 T cells, are essential players in tumor eradication, as the presence of tumor-infiltrating lymphocytes (TILs) in several cancers positively correlates with a good prognosis. To eliminate tumor cells, CD8 T cells recognize tumor antigens, which are MHC I-associated peptides present on the surface of tumor cells and either not expressed or expressed at very low levels on normal cells. Described herein is a proteogenomic approach using RNA sequencing data from cancer and matched normal mTEChi samples to identify non-tolerogenic tumor-specific antigens derived from (i) coding and non-coding regions of the genome, (ii) non-synonymous single-base mutations or short insertions / deletions, and more complex rearrangements, as well as (iii) endogenous retroelements, which function regardless of the sample's mutational load or complexity.SELECTED DRAWING: None

To provide AAV having modified transduction ability, the AAV including in its structure, various kinds of transducing genes including a clinically important transducing gene for a patient who requires a transducing gene.SOLUTION: There are provided: an isolation modification VP1 protein of an adeno-associated virus serotype 5 (AAV5) capsid, including one or more amino acid replacements for improving transduction efficiency, relative to VP1 protein of a wild type AAV5 capsid; and capsid and vector based on the isolation modification VP1 protein.SELECTED DRAWING: None

In some embodiments, provided are anti-GCC single domain antibodies (e.g., VHH domain antibodies) that bind GCC and chimeric antigen receptors (CARs) that comprise: the anti-GCC single domain antibodies in an extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain. Immune cells transduced with the disclosed CAR constructs and / or chimeric receptors can be used in cancer immunotherapy.

Compositions, methods, and systems for selecting polynucleotides for their activity as neuron-specific transcription factors are disclosed herein. [Solution] The system of the present invention may include a library of polynucleotides encoding reporter proteins and panneuronal markers, Gas proteins, and guide RNAs (gRNAs) that target putative transcription factors. A method for screening neuron-specific transcription factors is further provided.

In the present invention, factors attributable to nucleic acids that affect the dynamics of extracellular vesicles are screened.　A library of barcoded extracellular vesicles is provided.

The invention relates to the technical field of biology, and provides a method for constructing a bacterial mutant library and application thereof, and the method comprises the following steps: (1) based on a mutation site of a target protein, carrying out splitting treatment on coding nucleic acid of the target protein, and constructing a saturated mutation site fragment for coding the target protein; (2) constructing a first vector which contains an expression signal marker and an SUMO-FutC enzyme fragment and does not contain an IIS type restriction enzyme digestion site; (3) connecting the saturated mutation site fragment with a first vector to obtain a saturated mutation vector library; and (4) transferring the vectors in the saturated mutation vector library into bacteria to obtain the bacterial mutant library. The bacterial mutant library can be combined with a microfluidic technology to screen key functional sites and corresponding strains of a target protein, for example, a target strain with high yield of 2 '-fucosyllactose can be efficiently obtained, the yield of the target strain is 4.7-7.6 times that of a wild strain, meanwhile, the time, instrument and reagent cost is saved, and the operation requirement is low.

To provide a compositions and a method concerning an antibody or an antibody fragment that specifically binds to CD38.SOLUTION: A composition comprising an antibody or an antibody fragment, the antibody or antibody fragment comprising, as a constituent thereof, one or more complementarity determining regions or framework regions of a light chain variable region or a heavy chain variable region comprising an amino acid sequence selected from the group consisting of predetermined amino acid sequences.SELECTED DRAWING: Figure 7

The present disclosure relates to compositions and methods for the preparation, use and / or formulation of adeno-associated virus capsid protein variants.

The present invention provides an hBCMA-binding polypeptide comprising at least one motif that binds to hBCMA, wherein the peptide has the following structure: [N-terminal portion]-[Helix 1]-[Spacer portion]-[Helix 2]-[C-terminal portion], and the hBCMA-binding motif is the portion [Helix 1]-[Spacer portion]-[Helix 2]. The present invention further provides a pharmaceutical composition comprising the hBCMA-binding polypeptide, and the use of the hBCMA-binding polypeptide or the pharmaceutical composition for use as a medicament, particularly for the treatment or prevention of cancer.

To provide a CD19 composition and method for immunotherapy.SOLUTION: The invention provides a biocircuit system, an effector module, and a composition for cancer immunotherapy. The invention also provides a method for inducing an anticancer immune response in a subject.SELECTED DRAWING: None

To provide vaccines and methods.SOLUTION: Described herein are methods for identifying optimized antigenic pathogen polypeptides capable of inducing a broadly neutralizing immune response and associated T-cell responses to a pathogen, and nucleic acid sequences encoding such polypeptides. Also described are methods for determining whether a broadly neutralizing immune response is induced in a subject following immunization with an optimized antigenic pathogen polypeptide or a nucleic acid encoding the optimized pathogen polypeptide. Further described are nucleic acid molecules, polypeptides, vectors, cells, fusion proteins, pharmaceutical compositions, and their use as vaccines against pathogens, especially against emerging or re-emerging pathogens (particularly RNA viruses).SELECTED DRAWING: None

The presently disclosed subject matter relates to multispecific antibodies, e.g., bispecific antibodies and biepitopic antibodies, and methods for screening for such antibodies, and a novel antibody structure that can be used to screen for such bispecific antibodies and biepitopic antibodies. The present disclosure further provides bispecific anti-KLB antibodies and methods for treating diseases using these antibodies.

Disclosed are engineered virus-like particles (VLPs) and uses thereof, in which integral plasma membrane proteins are captured and displayed in their native conformation on the surface of the VLPs based on interactions between a viral scaffolding protein fused to a PDZ domain and a synthetic polypeptide of the cytoplasmic C-terminal tail of the target membrane protein.

The presently disclosed subject matter relates to multispecific antibodies, e.g., bispecific antibodies and biepitopic antibodies, and methods for screening for such antibodies, and a novel antibody structure that can be used to screen for such bispecific antibodies and biepitopic antibodies. The present disclosure further provides bispecific anti-KLB antibodies and methods for treating diseases using these antibodies.

Compositions of peptides modified to enhance HLA binding or T cell recognition while preserving reactivity to target neoepitopes enhance the activation of neoantigen-specific T cells. The method of use involves treating cancer by administering one or more of these peptides, which are produced by computer modeling.

The presently disclosed subject matter relates to multispecific antibodies, e.g., bispecific antibodies and biepitopic antibodies, and methods for screening for such antibodies, and a novel antibody structure that can be used to screen for such bispecific antibodies and biepitopic antibodies. The present disclosure further provides bispecific anti-KLB antibodies and methods for treating diseases using these antibodies.

To provide a novel cancer vaccine.SOLUTION: Disclosed herein is a protein fusion technology that allows the combination of one or more cancer vaccine epitopes with scaffold domains. Also disclosed herein are polypeptide and polynucleic acid compositions encompassed by the protein fusion technology and methods of using the same.SELECTED DRAWING: None

To provide a process for preparing a library of native state membrane proteomes and lipidomes in a form of saposin-derived particles.SOLUTION: Provided is a process for preparing a library of saposin lipoprotein particles where the library comprises a heterogenic mixture of saposin lipoprotein particles comprising different membrane lipids and optionally membrane protein compositions, where the process comprises the steps of: a) providing a mixture of crude membrane vesicles obtained from a cell or vesicle membrane of an archaeal, eukaryotic or prokaryotic organism, where the crude membrane vesicles contain both of the membrane lipids and membrane proteins from the source cell or vesicle membrane; b) contacting the mixture of step a) with the lipid binding polypeptide in a liquid environment; and c) allowing for self-assembly of the particles.SELECTED DRAWING: None

The present disclosure provides proteins that can be used as scaffolds to bind to specific targets, including specific proteins or peptides of interest, and fusion proteins having such scaffolds. Such proteins or peptides of interest may include disordered regions. The present invention also relates to various uses of the scaffolds, including diagnostic agents, therapeutic agents, detection reagents, and vaccines. Protein scaffolds can be tailored to specifically bind to targets using the methods described herein.

The present disclosure relates to compositions, methods, and processes for the preparation, use, and / or formulation of adeno-associated virus capsid proteins that contain targeting peptide inserts to enhance target tissue tropism.

The disclosure relates to compositions and systems comprising nucleic acid sequences that encode and amino acid sequences that comprise a first, second, and third region, each region forming a confirmational trimer and scaffold to associate with and identify certain epitopes against which Immunotherapeutics may bind. Methods of using the polypeptide sequences are also disclosed.

Disclosed herein are protein fusion technologies that allow for the combination of one or more cancer vaccine epitopes with a scaffold domain. Also disclosed herein are polypeptide and polynucleic acid compositions encompassed by the protein fusion technologies and methods of using them.

Disclosed herein are systems and methods for screening variant libraries for activity. Also disclosed herein are high-throughput methods for identifying candidate variants with gain-of-function biological activity in assays. The present disclosure also describes a method for identifying Erb-B2 receptor tyrosine kinase 2 (ERBB2) polypeptide variants associated with cancer. Figure 1A provides an overall overview of embodiments of the methods described herein. In some embodiments, the methods described herein may include one or more of steps 1-7 described in Figure 1A.

The present invention belongs to the field of monoclonal antibody technology and relates to a monoclonal antibody targeting activated protein C (aPC). The amino acid sequences of the heavy and light chains of the monoclonal antibody are shown in SEQ ID NOs. 5 to 26, and the CDR sequences thereof are shown in SEQ ID NOs. 27 to 92. The present invention also provides biomaterials related to the monoclonal antibody, which selectively bind to aPC but not to inactivated protein C. The present invention also provides the use of the monoclonal antibody and related biomaterials in the preparation of drugs for treating coagulation deficiencies or defects, as well as related treatment methods, which have broad application prospects.